Literature DB >> 26414081

Bone loss in HIV: a contemporary review.

Corrilynn O Hileman1, Allison Ross Eckard, Grace A McComsey.   

Abstract

PURPOSE OF REVIEW: Because of antiretroviral therapy (ART), people are living with HIV infection longer than ever before. As this patient group ages, it is expected that medical comorbidities such as osteoporosis and fragility fractures will increase. The purpose of this review is to address the epidemiology and what is known regarding the pathogenesis of bone loss in people living with HIV infection with a focus on recently published literature. RECENT
FINDINGS: HIV-infected individuals are at increased risk for low bone mineral density and bone fractures. The cause of bone loss in HIV is multifactorial including traditional risk factors some of which disproportionately affect HIV-infected individuals and alterations in bone metabolism due to ART, HIV viral proteins and chronic inflammation. Lifestyle modification, changing ART, calcium and vitamin D supplementation and pharmacologic treatment for osteoporosis may all be employed to abrogate bone loss in this patient group.
SUMMARY: Clinicians should be aware of the contributors to bone loss in people living with HIV in order to recognize high-risk individuals and to take appropriate steps to address modifiable risk factors to prevent future fracture.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26414081      PMCID: PMC4663974          DOI: 10.1097/MED.0000000000000200

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  61 in total

1.  Impact of Strength Training on Bone Mineral Density in Patients Infected With HIV Exhibiting Lipodystrophy.

Authors:  Wlaldemir R Santos; Walmir R Santos; Pedro P Paes; Isac A Ferreira-Silva; André P Santos; Natan Vercese; Dalmo R L Machado; Francisco José A de Paula; Eduardo A Donadi; Anderson M Navarro; Ana Paula M Fernandes
Journal:  J Strength Cond Res       Date:  2015-12       Impact factor: 3.775

2.  Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.

Authors:  Todd T Brown; Carlee Moser; Judith S Currier; Heather J Ribaudo; Jennifer Rothenberg; Theodoros Kelesidis; Otto Yang; Michael P Dubé; Robert L Murphy; James H Stein; Grace A McComsey
Journal:  J Infect Dis       Date:  2015-05-05       Impact factor: 5.226

3.  Low bone mineral density in patients with well-suppressed HIV infection: association with body weight, smoking, and prior advanced HIV disease.

Authors:  Katherine W Kooij; Ferdinand W N M Wit; Peter H Bisschop; Judith Schouten; Ineke G Stolte; Maria Prins; Marc van der Valk; Jan M Prins; Berthe L F van Eck-Smit; Paul Lips; Peter Reiss
Journal:  J Infect Dis       Date:  2014-09-01       Impact factor: 5.226

4.  Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy.

Authors:  P Rietschel; C Corcoran; T Stanley; N Basgoz; A Klibanski; S Grinspoon
Journal:  Clin Infect Dis       Date:  2000-11-02       Impact factor: 9.079

5.  Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels.

Authors:  Eugènia Negredo; Adolfo Diez-Pérez; Anna Bonjoch; Pere Domingo; Núria Pérez-Álvarez; Mar Gutierrez; Gracia Mateo; Jordi Puig; Patricia Echeverría; Roser Escrig; Bonaventura Clotet
Journal:  J Antimicrob Chemother       Date:  2015-03-13       Impact factor: 5.790

6.  Continuous antiretroviral therapy decreases bone mineral density.

Authors:  Birgit Grund; Grace Peng; Cynthia L Gibert; Jennifer F Hoy; Rachel L Isaksson; Judith C Shlay; Esteban Martinez; Peter Reiss; Fehmida Visnegarwala; Andrew D Carr
Journal:  AIDS       Date:  2009-07-31       Impact factor: 4.177

7.  HIV infection and bone mineral density in middle-aged women.

Authors:  Julia H Arnsten; Ruth Freeman; Andrea A Howard; Michelle Floris-Moore; Nanette Santoro; Ellie E Schoenbaum
Journal:  Clin Infect Dis       Date:  2006-02-24       Impact factor: 9.079

8.  Premature decline of serum total testosterone in HIV-infected men in the HAART-era.

Authors:  Vincenzo Rochira; Lucia Zirilli; Gabriella Orlando; Daniele Santi; Giulia Brigante; Chiara Diazzi; Federica Carli; Cesare Carani; Giovanni Guaraldi
Journal:  PLoS One       Date:  2011-12-09       Impact factor: 3.240

9.  The HIV proteins Tat and Nef promote human bone marrow mesenchymal stem cell senescence and alter osteoblastic differentiation.

Authors:  Carine Beaupere; Marie Garcia; Jerome Larghero; Bruno Fève; Jacqueline Capeau; Claire Lagathu
Journal:  Aging Cell       Date:  2015-04-07       Impact factor: 9.304

10.  Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen.

Authors:  Todd T Brown; Grace A McComsey; Martin S King; Roula B Qaqish; Barry M Bernstein; Barbara A da Silva
Journal:  J Acquir Immune Defic Syndr       Date:  2009-08-15       Impact factor: 3.771

View more
  17 in total

1.  Relationships Between Physical Activity and Bone Density in People Living with HIV: Results from the SATURN-HIV Study.

Authors:  Joseph D Perazzo; Allison R Webel; S M Khurshid Alam; Abdus Sattar; Grace A McComsey
Journal:  J Assoc Nurses AIDS Care       Date:  2018-03-28       Impact factor: 1.354

2.  The Influence of Exercise on Cardiovascular Health in Sedentary Adults With Human Immunodeficiency Virus.

Authors:  Allison R Webel; Joseph Perazzo; Christopher T Longenecker; Trevor Jenkins; Abdus Sattar; Margaret Rodriguez; Nate Schreiner; Richard A Josephson
Journal:  J Cardiovasc Nurs       Date:  2018 May/Jun       Impact factor: 2.083

Review 3.  HIV and Bone Complications: Understudied Populations and New Management Strategies.

Authors:  Michael T Yin; Todd T Brown
Journal:  Curr HIV/AIDS Rep       Date:  2016-12       Impact factor: 5.071

Review 4.  Contemporary Lifestyle Modification Interventions to Improve Metabolic Comorbidities in HIV.

Authors:  Kathleen V Fitch
Journal:  Curr HIV/AIDS Rep       Date:  2019-12       Impact factor: 5.071

5.  Impact of human immunodeficiency virus on 2-year revision rates following lumbar fusion for degenerative spinal conditions: a retrospective cohort study.

Authors:  Anna Maria Ifarraguerri; Alisa Malyavko; W Travis Stoll; Shalin Patel; Savyasachi Thakkar
Journal:  J Spine Surg       Date:  2021-12

6.  Brief Report: Undercarboxylated Osteocalcin Is Associated With Cognition in Women With and Without HIV.

Authors:  Ryan D Ross; Arnold Z Olali; Qiuhu Shi; Donald R Hoover; Anjali Sharma; Kathleen M Weber; Audrey L French; Heather McKay; Phyllis C Tien; Michael T Yin; Leah H Rubin
Journal:  J Acquir Immune Defic Syndr       Date:  2022-10-01       Impact factor: 3.771

7.  Effects of Vitamin D Supplementation on Bone Mineral Density and Bone Markers in HIV-Infected Youth.

Authors:  Allison Ross Eckard; Mary Ann OʼRiordan; Julia C Rosebush; Joshua H Ruff; Ann Chahroudi; Danielle Labbato; Julie E Daniels; Monika Uribe-Leitz; Vin Tangpricha; Grace A McComsey
Journal:  J Acquir Immune Defic Syndr       Date:  2017-12-15       Impact factor: 3.731

Review 8.  People Living With HIV: Implications for Rehabilitation Nurses.

Authors:  Joseph D Perazzo; Allison R Webel; Ellen McGough; Joachim Voss
Journal:  Rehabil Nurs       Date:  2018 May/Jun       Impact factor: 1.625

Review 9.  Bone Health in People Living With HIV: The Role of Exercise and Directions for Future Research.

Authors:  Joseph D Perazzo; Allison R Webel; Carl J Fichtenbaum; Grace A McComsey
Journal:  J Assoc Nurses AIDS Care       Date:  2017-10-04       Impact factor: 1.809

10.  Factors Associated with Bone Mineral Density and Bone Resorption Markers in Postmenopausal HIV-Infected Women on Antiretroviral Therapy: A Prospective Cohort Study.

Authors:  Christa Ellis; Herculina S Kruger; Michelle Viljoen; Joel A Dave; Marlena C Kruger
Journal:  Nutrients       Date:  2021-06-18       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.